#ESCCongress – RCT: In patients with A. Fibrillation who under | Cardiology
#ESCCongress– RCT: In patients with A. Fibrillation who underwent TAVR, Edoxaban was noninferior to Vit. K Antagonist regarding the composite primary outcome of adverse clinical events, but resulted in a higher incidence of major bleeding.